Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Goodbye flat lymphoma biology

Faria C., Dobaño-López C., Pérez-Galán P., Bezombes C.

Clinical Trial on Hip, published in FEBS Lett (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
FEBS Lett (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40741889
PMCID
PMC12558674
DOI
10.1002/1873-3468.70114
Citations
3

Abstract (original English)

B-cell lymphomas grow in aggregates, closely interacting with specific physical elements and cellular environments. While 2D culture systems have long been the standard in the field, current methodologies aim to better replicate lymphoma biology and its microenvironment in 3D. Significant progress has been made since the first 3D lymphoma cell line culture was developed in 2012. Subsequent advances in both cell line and patient-derived systems have incorporated key physical and cellular microenvironmental components. This Review compiles the relevant 3D non-Hodgkin lymphoma models available, outlining their main features, strengths, and limitations. Additionally, we highlight the critical gaps that must be addressed to develop robust, multiplexed, patient-derived B-cell lymphoma systems, which can serve as reliable avatars alongside clinical trials and contribute to the principles of the 3Rs in animal research. Impact statement In the last few years new B-cell lymphoma 3D models have emerged, with a special emphasis on patient-derived models. These systems are fundamental tools for precision medicine. This review provides translational researchers and clinician scientists with an excellent overview of these novel tools with their strong and weak points.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Cell Line, TumorAnimalsHumansLymphoma, B-CellTumor Microenvironment

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research